We are pioneering next generation oral treatments to revolutionize metabolic health.

Our mission is to redefine the management of the spectrum of metabolic disorders, from muscular wasting, diabetes to obesity, and other associated comorbidities, impacting millions of people globally.
We aim to transform therapeutic options through the development of small molecules with distinct and novel signaling profiles.
These molecules are specifically designed to avoid desensitization, enabling chronic use across a wide range of therapeutic applications.

Targeted β₂-adrenergic receptor agonists for diabesity therapeutics and beyond, ready for Phase II

Phase II. Our lead asset ATR-258 has advanced through Phase I clinical trials and is ready for the next phase.
Deep domain insights to β₂-adrenergic receptor signalling, with proprietary targeted agonists developed fuelling a pipeline expansion.
Advancing promising compounds, currently in preclinical stages, showing remarkable potential in repartitioning and altering muscle metabolism.

Recognised in The Journal Cell, describing the breakthrough identification of a novel array of β₂-adrenergic receptor agonists.
Unique proprietary platform with a strong IP-portfolio and pipeline.
Backed by global and local investors, including Flerie Invest, Korea Investment Partners (KIP), and a network of private investors.
Since our inception, we have successfully raised over EUR 20 million in funding.
Recognized by international organizations, securing over EUR 1.5 million in non-dilutive grants from Eurostars and SWELife, affirming the groundbreaking nature of our receptor signaling discoveries.